In Brief
Intact protein mass spectrometry allows determination of properties of protein complexes that are difficult to obtain through peptide-based methods. Gersch et al. introduce an analytical platform for the streamlined analysis of proteasome samples, revealing phosphorylation stoichiometries, inhibitor specificity, and sample heterogeneities.
SUMMARY
The proteasome is responsible for the majority of protein degradation within eukaryotic cells and proteasome inhibitors have gained blockbuster status as anticancer drugs. Here, we introduce an analytical platform comprising reverse phase chromatography, intact protein mass spectrometry, and customized data analysis that allows a streamlined investigation of proteasome integrity and posttranslational modifications. We report the complete mass spectrometric assignment of all subunits of the yeast core particle, as well as of the human constitutive 20S proteasome and the human immunoproteasome, including phosphorylated isoforms of a7. Importantly, we found several batches of commercially available immunoproteasome to also contain constitutive catalytic subunits. Moreover, we applied the method to study the binding mechanisms of proteasome inhibitors, both validating the approach and providing a direct readout of subunit preferences complementary to biochemical methods. Collectively, our platform facilitates an easy, reliable and comprehensive detection of different types of covalent modifications on multisubunit protein complexes with high accuracy.
The controlled degradation of proteins is of pivotal importance for cellular proteostasis. In eukaryotic cells, the proteasome is responsible for the majority of protein breakdown in both cytosol and nucleus (Hershko and Ciechanover, 1998; Kisselev and Goldberg, 2001; Voges et al., 1999) . The 20S proteasomal core particle (CP) is composed of four seven-membered rings that are stacked corresponding to an a7:b7:b7:a7 stoichiometry (Figure 1A) (Groll et al., 1997; Lowe et al., 1995) . Among all subunits, only b1c, b2c, and b5c are catalytically active. During an inflammatory state, they can be exchanged with alternative b1i, b2i, and b5i subunits to form the immunoproteasome (Huber et al., 2012; Unno et al., 2002) . Every single catalytic subunit has its distinct cleavage site preference (Nussbaum et al., 1998) but they all share the general architecture as threonine protease, which gives rise to a number of intricate inhibition mechanisms by covalent inhibitors Groll et al., 2000) .
Both the constitutive proteasome (cCP) as well as the immunoproteasome (iCP) are attractive drug targets for the treatment of cancer and autoimmune diseases, respectively.
Serine/threonine phosphorylation, N-terminal truncation, and N-terminal acetylation are the most common posttranslational modifications of the 20S proteasome Uttenweiler-Joseph et al., 2008) . Sample heterogeneity has become apparent from 2D gel electrophoresis due to multiple isoforms and has been analyzed via proteolytic digests with peptide-based mass spectrometry (Huang and Burlingame, 2005) . While routinely feasible, this approach is characterized by several working steps and incomplete sequence coverage (Claverol et al., 2002; Wang et al., 2007) . Intact protein mass spectrometry (IPMS) has been applied to proteasomes that have identical a and b subunits (Loo et al., 2005; Sharon et al., 2007) . Approaches to study eukaryotic proteasomes by IPMS have been complicated by sample complexity and have thus been hampered by incomplete coverage as well as limited applicability (Dechavanne et al., 2013; Groll et al., 1999; Russell et al., 2013) . MALDI-TOF analysis after 2D gel separation allowed the identification of all subunits (Uttenweiler-Joseph et al., 2008) , however some isoforms could not be resolved (Bousquet-Dubouch et al., 2011) . Most recently, a top-down analysis (Loo et al., 1990 ) with several fragmentation methods on a high-end Fourier transform-ion cyclotron resonance (FT-ICR) spectrometer allowed the investigation of cCP and its modifications after reverse phase separation (Lakshmanan et al., 2014) . In this approach, spectra had to be selected manually for processing and a simulated gel view was used for plotting the results. This procedure illustrates a common challenge with complex samples for IPMS, since these samples typically consist of more species than there are peaks in the total ion current chromatogram. This not only makes the detection of all species by manual selection of spectra challenging but also prevents a robust and comprehensive assessment of sample properties. Here, we introduce an easy to implement and broadly applicable platform with automated software that enables comprehensive IPMS analysis of proteasome integrity, function, and inhibition.
We first validated the sample complexity by obtaining highresolution mass spectra from online desalted yeast 20S proteasome (yCP) on an FT-ICR spectrometer. As anticipated, the deconvoluted data were of poor quality due to large spectral crowding. We then used an optimized gradient for C4-based reverse phase chromatography that enabled subunit separation ( Figure 1B Figure S1 and Table S1 . Ac denotes whether the subunit is acylated (+) or not (À). The N-termini of b1, b2, b5, b6, and b7 are protected against N-terminal acetylation by propeptides that are cleaved off autoprocessively during assembly of the proteasome (Groll et al., 1999) . (Zhang and Marshall, 1998) . However, any deconvolution program that features a command-line-based interface can be implemented. In order to visualize the results, a sample map can be constructed by plotting detected protein masses over the mean retention times of the analyzed scans. We then subjected these data to intensity-weighted k-means clustering. Clusters on the yCP sample map could be assigned to all 14 subunits of the proteasome with distinct posttranslational modifications (phosphorylation, truncation, and acetylation), in agreement with annotations in the Uniprot database ( Figure 1C ; Table 1 ). We then selected spectra with maximal intensity for each subunit and performed high accuracy mass determination using deconvolution with the Xtract algorithm and Gauss fitting ( Figure S1 ). Such analysis enabled us to obtain high-quality spectra in isotopic resolution of the b2 subunit that had so far been elusive to mass spectrometry (Groll et al., 1999) (Figures 1D and 1E ). While no intensity was observed for the mass anticipated for subunit a7, we obtained two clusters that were heavier by +160 Da and +240 Da and were thus assigned to 2-fold and 3-fold phosphorylated isoforms, respectively ( Figure 1F ). For all other subunits, no such clusters corresponding to phosphorylated isoforms were found. We determined the stoichiometry of these isoforms through deconvolution with four different algorithms, which gave similar results. 82.5% ± 2.2% (mean ± SD) of the a7 signal was derived from the 3-fold phosphorylated isoform while correspondingly 17.5% ± 2.2% was derived from the 2-fold phosphorylated isoform (Table S1 ). a7 phosphorylation at Ser258, Ser263, and Ser264 was previously identified by proteomic experiments (Soufi et al., 2009) . Here, we report that a7 phosphorylation is the only major phosphorylation observed in yCP. Our data on the protein level thus complement proteomic data with the quantitative phosphorylation stoichiometry, which can be difficult to obtain through peptide-based methods (Carpy et al., 2014) . Next, we turned to the human constitutive proteasome and to the human immunoproteasome and subjected them to a similar analysis (Figure 2 ; Figure S2 ). Our analytical platform allowed for the complete assignment of all subunits with mass accuracies <1 Da (Table 2; Figure S2 ). Monophosphorylation represented the dominant modification of a7 while all other subunits were only detected as unphosphorylated isoforms. This finding is in agreement with previous results (Lakshmanan et al., 2014; Olsen et al., 2010; Zong et al., 2008) . The degree of a7 monophosphorylation was determined highly reproducibly and robustly from ten independent samples and three different cCP batches to be 95.7% ± 1.1% (mean ± SD, Table S2 ). a7 phosphorylation has been implicated with an increased 20S-19S interaction (Bose et al., 2004) . While the maps of the cCP samples were generally of high quality (Figure 2A ), the data derived from three different batches of commercially obtained iCP showed a higher degree of heterogeneity. Importantly, all three iCP samples contained substantial amounts of the respective constitutive subunits, partly as the only detectable catalytic species (as for b2c and Figure S2 , Figure S3 , and Table S2 .
b5c in iCP sample 2, Figure 2C ) while in sample 3 ( Figure 2D ) the catalytic b1i subunit was apparently missing. Whereas mouse immunoproteasome can be purified from mouse liver after iCP enrichment through viral infection, human iCP is typically purified from cells that express both the constitutive and immunoproteasome-specific subunits, likely explaining these results. In addition, the existence of intermediary-type proteasomes with a mixed composition of catalytic subunits has been reported (Bousquet-Dubouch et al., 2011) . We detected additional clusters shifted to lower masses with regard to the parent noncatalytic subunits which were assigned to N-terminal truncation products (marked in dashed boxes). In some cases, the fulllength isoform was completely missing (as a6 in sample 3, Figure 2D ) or had become a minor species (as a4 in sample 2, Figure 2C) . Unexpectedly, the b2i subunit appeared as an isoform in all samples as the major species that was $17 Da lighter than the canonical sequence would suggest. This mass difference would be consistent with an Asn / Pro or with a Met / Asn mutation (more complicated patterns of mutations are possible as well; however, the precise determination of the mass difference is precluded by the presence of multiple oxidized species). Of note, variants corresponding to point mutations as a result of SNPs have been described for other subunits (Uttenweiler-Joseph et al., 2008) . While our analysis cannot match the localization precision of peptide-based methods, it provides insights into sample integrity that are difficult to obtain from conventional proteomic approaches. All observed alterations might have important consequences for structural integrity and catalytic activity of the proteasome. Mass spectrometry (MS)-based subunit mapping can assess this heterogeneity (Claverol et al., 2002) and variance in different samples beyond the capabilities of 2D gel electrophoresis, and we believe this heterogeneity has to be considered when discussing results derived from such immunoproteasome batches. We also established the analysis on a common low-resolution ion-trap mass spectrometer ( Figure S3 ), ensuring a broad applicability of the method. Clinically applied proteasome inhibitors such as bortezomib (Velcade) and carfilzomib (Kyprolis) have gained blockbuster status as anticancer drugs (Huber et al., 2012; Kisselev and Goldberg, 2001 ). Moreover, immunoproteasome-specific inhibitors are currently being developed by both industrial and academic groups with promising results against diseases characterized by aberrant immune function (Basler et al., 2014) . Different statements have been made in the literature regarding the combination of subunits that needs to be inactivated to evoke cytotoxicity, although b5c/b5i are generally assumed to be the most important targets. Several techniques exist to assess subunit specificity of proteasome inhibitors. Fluorogenic substrates are widely used, however, results are at times questioned because of cross-reactivity with other proteases or similar substrate preferences (e.g. b5c and b1i). Moreover, subunit-specific activity-based probes exist (Li et al., 2014) ; however, their readout by gel fluorescence imaging restricts its use for the analysis of catalytic subunits and does not inform about inhibition mechanisms. Crystallography was recently applied for this purpose (Stein et al., 2014) but, despite the detailed insights, its low throughput and restriction to well-crystallizable forms of the proteasome limit its application .
We reasoned that our approach might be complementing these techniques for covalent inhibitors and we consequently (Dechavanne et al., 2013) . Localization of cCP subunit modifications through top-down analysis has been reported recently by Lakshmanan et al. (2014) . a a7 was found to be monophosphorylated. The majority of b2i appeared as a lighter isoform (À17 Da) in all samples; only a weak signal for the canonical b2i was detected.
applied our analytical platform to the investigation of subunit specificity and inhibitor mechanisms. First, we analyzed the effects of the well-characterized, irreversibly binding inhibitor carfilzomib on the catalytic subunits of cCP (Harshbarger et al., 2015; Huber et al., 2015) ( Figure 3A) . Overlay of the deconvolution maps clearly showed the disappearance of the clusters representing unmodified b2c and b5c subunits while nearby new clusters appeared; other subunits remained unchanged. We then selected spectra for Xtract deconvolution and found that these new clusters correspond to masses of b2c:carfilzomib and b5c:carfilzomib adducts ( Figures 3B-3E) . A minor cluster with a b1c:carfilzomib adduct was identified, which is in agreement with incomplete binding as evident from the deconvolution spectra ( Figure 3B ). When treated with a lower concentration (2.5 mM, see Figure S4B ), modification of only b5c was observed, which is in line with the published b5c selectivity. Furthermore, we analyzed samples of cCP incubated with MG-132 and a vinyl sulfone-based inhibitor ( Figures S4C-S4E ), all consistently showing b5c-modified species. Notably, due to the protein concentration in the sample (0.5 mg/ml, corresponding to 1.4 mM per catalytic subunit), this analysis cannot be used to infer compound potencies as these are usually in the nanomolar range. However, a competition experiment with several covalent inhibitors present in the reaction can be used for a relative comparison of compound potencies. Collectively, the platform reported herein facilitates a fast, reliable, and comprehensive evaluation of different proteasome samples (Figure 4) . We have recently applied this method to the study of short-lived species and novel chemical modifications, demonstrating its capacity to contribute to the investigation of inhibitor binding mechanisms . Moreover, it opens the possibility of screening for covalent binders of noncatalytic subunits. Its capabilities greatly surpass 2D gel electrophoresis and we therefore expect it to be useful for quality control and sample characterization purposes. In addition, the platform can be used to compare proteasome samples derived from cells with different genomic backgrounds in order to assist in the investigation of proteasome assembly, subunit processing, and regulation through posttranslational modifications. Compiled versions and documentation of the rolling-window deconvolution analysis program are available for download at http://www.oc2.ch.tum.de free of charge.
SIGNIFICANCE
IPMS is a powerful tool that can inform about protein complex integrity and the stoichiometry of posttranslational modification, two properties that are difficult to obtain through peptide-based mass spectrometric methods. However, there are typically more species than peaks in the total ion current chromatogram in complex samples, which makes the detection of all species by manual selection of spectra challenging. Here, we introduce a program that facilitates an automated, comprehensive data analysis, and creates data for an intuitive visualization of the results in the form of a sample map. We apply this analysis technique to the investigation of several proteasome samples, validating the approach, proving its complementarity to existing methods, and showing its usefulness in protein biochemistry and chemical biology research. 
EXPERIMENTAL PROCEDURES Sample Preparation
Yeast proteasome was freshly purified from Saccharomyces cerevisiae as described previously (Groll et al., 2006) . Human constitutive proteasome and human immunoproteasome were obtained from Boston Biochem. Inhibitors were either purchased from Selleckchem or synthesized as described previously (Stein et al., 2014) . Proteasome solution (0.5 mg/ml) in 50 mM HEPES (pH 7.6), 100 mM NaCl, 1 mM DTT (for cCP and iCP) in 20 mM MES (pH 6.8), 150 mM NaCl (for yCP) was incubated with indicated inhibitor concentrations for 12 hr at room temperature and then brought to 30% (v/v) acetonitrile.
Reverse Phase Chromatography and IPMS Analyses were carried out on a Dionex UltiMate 3000 high-performance liquid chromatography (HPLC) system coupled to a Thermo Scientific LTQ-FT Ultra mass spectrometer with an electrospray ionization (ESI) source (room temperature; ionization voltage, 3.9 kV; tube lens, 110 V; capillary voltage, 20 V; sheath gas, auxiliary gas, and sweep gas, off). A heated ESI source could also be used (vaporizer temperature, 70 C; ionization voltage, 4.45 kV; tube lens, 120 V; capillary voltage, 30 V; sheath gas, 30 arb; auxiliary gas, 10 arb; sweep gas, off), demonstrating the broad applicability and transferability of the method. Eluent A consisted of water with 0.1% formic acid, eluent B consisted either of 90% acetonitrile and 10% water with 0.1% formic acid or 100% acetonitrile with 0.1% formic acid. All solvents were of liquid chromatography LC/MS grade (Sigma-Aldrich). Samples (10 ml, corresponding to 4.7 pmol/3.5 mg of proteasome per run) were separated on a C4 column (BioBasic-4, Thermo Scientific, 150 mm 3 1 mm, 5 mm; flow, 0.050 ml/min) with a gradient from 30% to 60% B over 60 min preceded by a 15 min equilibration step at 30% B and followed by a washing step at 100% B for 5 min. The mass spectrometer was run in positive mode, collecting full scans at high resolution (R = 200,000) from m/z 500 to m/z 2,000. For the low-resolution experiment, the sample was analyzed on a Dionex UltiMate 3000 HPLC system coupled to a Thermo Scientific LCQ Fleet mass spectrometer with a heated ESI source (source temperature, 39 C; ionization voltage, 4.45 kV; tube lens, 90 V; capillary voltage, 31 V; sheath gas, 30 arb; auxiliary gas, 10 arb; sweep gas, off). Eluent A consisted of water with 0.1% formic acid, eluent B consisted of 100% acetonitrile with 0.1% formic acid. All solvents were of LC/MS grade (Sigma-Aldrich). The sample was separated on a C4 column (BioBasic-4, Thermo Scientific, 150 mm 3 1 mm, 5 mm; flow, 0.050 ml/min) with a gradient from 30% to 60% B over 60 min proceeded by a 15 min equilibration step at 30% B and followed by a washing step at 100% B for 5 min. The mass spectrometer was run in positive mode collecting ion-trap scans at scan rate ''normal'' from m/z 300 to m/z 2,000.
Data Analysis
Xcalibur raw files were processed using customized software (RoWinPro, available for download at http://www.oc2.ch.tum.de) with rolling-window deconvolution analysis. The software uses the Xcalibur developer kit (XDK) to retrieve and average scans (window size, 10 scans for high-resolution data, 40 scans for low-resolution data; parameters can be specified in a graphical user interface) and analyzes them with the Znova deconvolution algorithm as implemented in the commercially available software Promass from Novatia, LLC (Zhang and Marshall, 1998 ) (input, 600-1,600 m/z; output, 18,000-36,000 Da; 1 Da mass step size; peak width, 3; merge width, 0.3; minimum score, 2; S/N threshold, 2; smooth width, 7; number of smooths, 2). Output files contain a list of detected species (retention time in minutes, mass in Daltons, intensity in arbitrary units) and were plotted with Microcal OriginPro 9.1 with a cut-off at 80% of the summed intensity (usually corresponding to the top 10%-50% of all data points) to reduce noise. The color scale was set to arbitrary values in order to fully cover the intensity range of the analyzed sample. Spectra containing subunits of interest were subsequently averaged with Xcalibur and analyzed by Thermo Scientific Xtract (Senko et al., 1995) for deconvolution and quantification. Gauss fits of deconvoluted Xtract spectra were carried out with Microcal OriginPro. MagTran (Zhang and Marshall, 1998 ) and Mann's Algorithm (Mann et al., 1989 ) (as implemented in MagTran) were used to confirm deconvolution results. Intensity-weighted k-means clustering (initial clusters, 20) was carried out with OriginPro and MATLAB. Cluster centers were plotted as crosses. See Figure 4 for a visual depiction of the workflow and the User Guide available online for further details on the analysis software.
